PD-L1-positive NSCLC

Advertisement

cGxPJobs Banner

Akeso Reports Ivonescimab OS Benefit in HARMONi-2

Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...

By cGxPwire Editor
September 4, 2026

Read More

Advertisement

cGxPJobs

Directory